Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trichosanthin is a ribosome-inactivating protein (RIP) isolated from the root tuber of the Chinese medicinal herb Trichosanthes kirilowii Maxim. Traditionally used as an abortifacient in Chinese medicine (notably as part of Tian Hua Fen), it was later purified for clinical use to reduce side effects[1][2]. Trichosanthin acts as an rRNA N-glycosylase by hydrolyzing and depurinating adenylic acid at position 4324 in the α-sarcin/ricin loop on 28S rRNA of eukaryotic ribosomes, thereby inhibiting protein synthesis and leading to cell death[1][6][8]. It has demonstrated multiple pharmacological properties including immunomodulatory, anti-tumor (notably against gastric, colorectal, and non-small cell lung cancer), and antiviral activities—most notably blocking HIV replication and destroying HIV-infected macrophages[2][3][4][5]. Its mechanism also involves interaction with chemokine receptors such as CCR5 and CXCR4. Clinical studies have explored its use in HIV infection (Phase 2 trials) and various cancers; however, adverse reactions like immune responses and short plasma half-life have limited its broader application. Modifications such as immunotoxins or PEGylation have been investigated to improve its pharmacological profile[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trichosanthin.